Last reviewed · How we verify
Pantoprazole Sodium
Pantoprazole suppresses gastric acid by covalently binding the (H+, K+)-ATPase enzyme at parietal cells.
Pantoprazole sodium is a proton pump inhibitor indicated for GERD with erosive esophagitis and pathological hypersecretory conditions in adults, with a short one-hour half-life and extensive hepatic metabolism. The drug demonstrates strong efficacy with common adverse reactions including headache, diarrhea, and nausea occurring in >2% of patients. Major contraindications include hypersensitivity to benzimidazoles and concurrent use with rilpivirine-containing antiretrovirals, with significant interactions requiring monitoring for warfarin and other antiretrovirals. Long-term use requires monitoring for serious adverse effects including hypomagnesemia, bone fracture risk, and Clostridioides difficile-associated diarrhea.
At a glance
| Generic name | Pantoprazole Sodium |
|---|---|
| Sponsor | Pfizer |
| Drug class | Proton pump inhibitor (PPI) |
| Target | (H+, K+)-ATPase enzyme |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
| First approval | 2000 |
Mechanism of action
Pantoprazole is a proton pump inhibitor that works by covalently binding to the (H+, K+)-ATPase enzyme system located at the secretory surface of gastric parietal cells. This binding suppresses the final step in gastric acid production, leading to inhibition of both basal and stimulated gastric acid secretion regardless of the stimulus. The antisecretory effect persists longer than 24 hours for all tested doses ranging from 20 mg to 120 mg, providing sustained acid suppression.
Approved indications
- Erosive esophagitis
- Gastric Hypersecretory Conditions
- Gastroesophageal reflux disease
- Maintenance of Healing Erosive Esophagitis
- Multiple endocrine adenomas
- Peptic ulcer
- Zollinger-Ellison syndrome
Common side effects
- Nasopharyngitis
- Diarrhoea
- Contusion
- Epistaxis
- Atrial fibrillation
- Abdominal pain upper
- Constipation
- Diabetes mellitus
- Arthralgia
- Back pain
- Dizziness
- Haematuria
Serious adverse events
- Anaemia
- Thrombocytopenia
Drug interactions
- Rilpivirine-containing products
- Atazanavir
- Nelfinavir
- Saquinavir
- Warfarin
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pantoprazole Sodium CI brief — competitive landscape report
- Pantoprazole Sodium updates RSS · CI watch RSS
- Pfizer portfolio CI